These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 28228152)
1. Cardiac metastasis from colon cancer effectively treated with 5-fluorouracil, leucovorin, and oxaliplatin (modified FOLFOX6) plus panitumumab: a case report. Tsujii Y; Hayashi Y; Maekawa A; Fujinaga T; Nagai K; Yoshii S; Sakatani A; Hiyama S; Shinzaki S; Iijima H; Takehara T BMC Cancer; 2017 Feb; 17(1):152. PubMed ID: 28228152 [TBL] [Abstract][Full Text] [Related]
2. Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab. Seront E; Marot L; Coche E; Gala JL; Sempoux C; Humblet Y Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S11-4. PubMed ID: 20189054 [TBL] [Abstract][Full Text] [Related]
3. [A case report of advanced mucinous adenocarcinoma of the transverse colon with peritoneal dissemination effectively treated by multidisciplinary approach with a focus on FOLFOX4 therapy combined with panitumumab]. Asano T; Negita M; Uemura T; Takagi D; Hattori M; Kamiya I Gan To Kagaku Ryoho; 2012 Jul; 39(7):1147-9. PubMed ID: 22790058 [TBL] [Abstract][Full Text] [Related]
4. Successful Treatment with Modified FOLFOX6 and Panitumumab in a Cecal Cancer Patient Undergoing Hemodialysis. Kobayashi M; Endo S; Hamano Y; Imanishi M; Akutsu D; Sugaya A; Ochi D; Moriwaki T; Hyodo I Intern Med; 2016; 55(2):127-30. PubMed ID: 26781010 [TBL] [Abstract][Full Text] [Related]
5. [The chemotherapy with mFOLFOX6 for advanced colon cancer was effective for gastric cancer - a case report]. Shimoishi K; Muto Y; Asakage M; Yamada Y Gan To Kagaku Ryoho; 2012 Jul; 39(7):1127-30. PubMed ID: 22790053 [TBL] [Abstract][Full Text] [Related]
7. [Long-Term Effectiveness of Chemotherapy Containing mFOLFOX6 plus Panitumumab and 5-FU/l-LV plus Panitumumab after Primary Tumor Resection in a Case of Ascending Colon Carcinoma and Multiple Hepatic Metastases]. Kitahama T; Gomyo Y; Okada I; Akita N; Ikeno T; Miyamoto H Gan To Kagaku Ryoho; 2019 Apr; 46(4):709-712. PubMed ID: 31164512 [TBL] [Abstract][Full Text] [Related]
8. Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report. Toyama Y; Ushigome T; Watanabe K; Kitamura H; Onda S; Saito R; Yoshida S; Kawahara H; Yanagisawa S; Yanaga K World J Surg Oncol; 2012 Jun; 10():129. PubMed ID: 22747970 [TBL] [Abstract][Full Text] [Related]
9. FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases. Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K Gan To Kagaku Ryoho; 2011 Jul; 38(7):1205-8. PubMed ID: 21772113 [TBL] [Abstract][Full Text] [Related]
10. [Preoperative chemotherapy with modified FOLFOX + panitumumab for the treatment of descending colon cancer with multiple liver metastases - a case study]. Yagi Y; Yamazaki T; Iwaya A; Manabe S Gan To Kagaku Ryoho; 2015 Jan; 42(1):109-12. PubMed ID: 25596691 [TBL] [Abstract][Full Text] [Related]
11. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465 [TBL] [Abstract][Full Text] [Related]
12. [A case of advanced colon cancer with peritoneal dissemination effectively treated with modified FOLFOX6 chemotherapy]. Tanaka K; Hirai K; Ogawa H; Toya H; Totsuka O; Yoshinari D; Sunose Y; Takeyoshi I Gan To Kagaku Ryoho; 2012 Jun; 39(6):993-5. PubMed ID: 22705700 [TBL] [Abstract][Full Text] [Related]
13. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916 [TBL] [Abstract][Full Text] [Related]
14. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. Watanabe J; Muro K; Shitara K; Yamazaki K; Shiozawa M; Ohori H; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Hihara M; Soeda J; Misumi T; Yamamoto K; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T JAMA; 2023 Apr; 329(15):1271-1282. PubMed ID: 37071094 [TBL] [Abstract][Full Text] [Related]
15. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. McRee AJ; Davies JM; Sanoff HG; Goldberg RM; Bernard S; Dees EC; Keller K; Ivanova A; O'Neil BH Cancer Chemother Pharmacol; 2014 Jul; 74(1):117-23. PubMed ID: 24819684 [TBL] [Abstract][Full Text] [Related]
16. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With Rossini D; Antoniotti C; Lonardi S; Pietrantonio F; Moretto R; Antonuzzo L; Boccaccino A; Morano F; Brugia M; Pozzo C; Marmorino F; Bergamo F; Tamburini E; Passardi A; Randon G; Murgioni S; Borelli B; Buonadonna A; Giordano M; Fontanini G; Conca V; Formica V; Aglietta M; Bordonaro R; Aprile G; Masi G; Boni L; Cremolini C J Clin Oncol; 2022 Sep; 40(25):2878-2888. PubMed ID: 35666229 [TBL] [Abstract][Full Text] [Related]
17. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. García-Foncillas J; Díaz-Rubio E Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651 [TBL] [Abstract][Full Text] [Related]
18. [A case of ascending colon cancer with local recurrence responding completely to alternating modified-FOLFOX6 and FOLFIRI regimens(modified-FIREFOX regimen)]. Matsutani T; Sasajima K; Suzuki S; Matsushita A; Maruyama H; Matsuda A; Miyamoto M; Yokoyama T; Sugiura A; Yanagi K; Nishi Y; Arai H; Wakabayashi H; Tajiri T Gan To Kagaku Ryoho; 2009 Mar; 36(3):505-7. PubMed ID: 19295282 [TBL] [Abstract][Full Text] [Related]
19. A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only. Bendell JC; Zakari A; Peyton JD; Boccia R; Moskowitz M; Gian V; Lipman A; Waterhouse D; LoCicero R; Earwood C; Lane CM; Meluch A Oncologist; 2016 Mar; 21(3):279-80. PubMed ID: 26911408 [TBL] [Abstract][Full Text] [Related]
20. The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer. Jia J; Zhang P; Gou M; Yang F; Qian N; Dai G Dis Markers; 2019; 2019():6812045. PubMed ID: 30805037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]